Biological E’s Corbevax could be the most affordable Covid vaccine in India

June 9, 2021 Gubba Pharma In E News

Biological E’s Corbevax, which is undergoing Phase 3 trials, could well be the most affordable vaccine in India priced at below Rs 500 for two doses, according to a report in Times of India.
Corbevax, a recombinant protein vaccine, has shown promising results in Phase 1 and 2 trials. The company hasn’t finalised the pricing so far.
The report mentioned an interview that the Biological E Managing Director Mahima Datla had given to the paper where she hinted at the same.
Biological E is working with Baylor College of Medicine (BCM), Texas, to make Corbevax.
Professor Peter Hotez, Dean for the National School of Tropical Medicine at the Baylor College of Medicine in Houston, Texas, in an interview to Times Now, had claimed that the vaccine will be robust against a number of Covid variants.
Centre has placed an order of 30 crore vaccines with Biological E making an advance payment of Rs 1,500 crore.
Covishield made by the Serum Institute of India is available at Rs 600 per dose at private hospitals while for state governments it is available at Rs 300 per dose. Bharat Biotech’s Covaxin is available at Rs 1,200 per dose at private hospitals while for state governments it is priced at Rs 400 per dose.
Sputnik V will be available at Rs 995 per dose until its domestic production begins.
The government has said that it will be able to vaccinate all adults before December end. Centre’s vaccination policy has come under criticism and the country’s top court has asked the Centre to explain the rationale behind its policy.
India has seen a steady decline in Covid cases after surging to more than 4 lakh cases a day in May. The daily count dipped to 1,20,529 fresh COVID-19 cases on Saturday.

Source : economictimes.indiatimes

Gubba Group

About the author

Gubba Group: